China
Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovati...
February 18, 2025 | News
Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1...
February 17, 2025 | News
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
February 17, 2025 | News
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (...
February 14, 2025 | News
Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...
February 14, 2025 | News
Akeso, Inc. announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION...
February 13, 2025 | News
AIM Vaccine Co, a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA s...
February 12, 2025 | News
BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application f...
February 11, 2025 | News
Keymed Biosciences announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug A...
February 10, 2025 | News
Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance tr...
February 07, 2025 | News
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has rece...
February 07, 2025 | News
Shanghai Henlius Biotech, Inc. announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Redd...
February 07, 2025 | News
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel anti...
February 06, 2025 | News
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant A...
January 31, 2025 | News
Most Read
Bio Jobs
News